MedPacto
Scope
Date
~
-
Bio & Pharma
MedPacto gets FDA OK for colorectal cancer drug clinical trial
South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its I...
Jan 03, 2024 (Gmt+09:00)
-
Bio & Pharma
MedPacto's anti-cancer substance designated as US FDA fast-track item
South Korean biotech company MedPacto Inc. ’s Vactosertib monotherapy for osteosarcoma patients has been designated as a fast-track developmen...
Jan 18, 2023 (Gmt+09:00)
-
Biotech
Korea’s MedPacto, Merck plan phase 3 trials of colorectal cancer drug
MedPacto Inc., a South Korean biotechnology company that develops therapeutics for cancer and autoimmune diseases, has agreed with global drugmaker ...
Dec 15, 2021 (Gmt+09:00)